MS-553
Diabetic Macular Edema (DME) / Diabetic Retinopathy (DR)
Key Facts
About MingSight Pharmaceuticals
MingSight Pharmaceuticals is a private, clinical-stage company developing selective PKC inhibitors, a drug class with a history of challenges. Its lead candidate, MS-553, is an oral, selective PKC inhibitor with promising early data in diabetic macular edema (DME) and chronic lymphocytic leukemia (CLL/SLL), particularly in patients resistant to BTK inhibitors. The company leverages a dual-therapeutic focus in ophthalmology and oncology to de-risk development and maximize the platform's value. Founded in 2015 by an experienced team, MingSight is positioned to address significant shortcomings of earlier, non-selective PKC inhibitors.
View full company profileAbout MingSight Pharmaceuticals
MingSight Pharmaceuticals is a private, clinical-stage company developing selective PKC inhibitors, a drug class with a history of challenges. Its lead candidate, MS-553, is an oral, selective PKC inhibitor with promising early data in diabetic macular edema (DME) and chronic lymphocytic leukemia (CLL/SLL), particularly in patients resistant to BTK inhibitors. The company leverages a dual-therapeutic focus in ophthalmology and oncology to de-risk development and maximize the platform's value. Founded in 2015 by an experienced team, MingSight is positioned to address significant shortcomings of earlier, non-selective PKC inhibitors.
View full company profileTherapeutic Areas
Other Diabetic Macular Edema (DME) / Diabetic Retinopathy (DR) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Aptamer Program | Drive Therapeutics | Pre-clinical |